Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · Real-Time Price · USD
0.9100
-0.0400 (-4.21%)
At close: May 26, 2026, 4:00 PM EDT
0.8901
-0.0199 (-2.19%)
After-hours: May 26, 2026, 6:36 PM EDT
Aprea Therapeutics Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, Aprea Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $4.30. The average 1-year stock price forecast is 372.53% higher than the current stock price, while the lowest is $1.20 (+31.87%) and the highest is $6.00 (+559.34%).
Price Target: $4.30 (+372.53%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Aprea Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Buy Reiterates $10 → $5 | Buy | Reiterates | $10 → $5 | +449.45% | May 14, 2026 |
| Wedbush | Wedbush | Buy Reiterates $7 → $6 | Buy | Reiterates | $7 → $6 | +559.34% | May 14, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $4 → $1.2 | Buy | Maintains | $4 → $1.2 | +31.87% | Mar 31, 2026 |
Financial Forecast
Revenue This Year
727.60K
from 285.76K
Increased by 154.62%
Revenue Next Year
1.54M
from 727.60K
Increased by 111.52%
EPS This Year
-0.78
from -1.93
EPS Next Year
-0.71
from -0.78
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 2.2M | 4.8M | ||||||
| Avg | 727,597 | 1.5M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 686.3% | 553.1% | ||||||
| Avg | 154.6% | 111.5% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.55 | -0.44 | |||
| Avg | -0.78 | -0.71 | |||
| Low | -0.93 | -1.03 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.